DeepMed Research

Amylyx Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 384

Market Cap: $145M

Website: http://www.amylyx.com

Clinical Trials

Avexitide for Treatment of Post-Bariatric Hypoglycemia

Phase 3

Recruiting

Conditions: Post Bariatric Hypoglycemia

Interventions: Other: Placebo
Drug: Avexitide

First Posted Date: 2024-12-24

Last Posted Date: 2025-05-07

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 75

Registration Number: NCT06747468

Locations: 🇺🇸
Stanford Health Care - Endocrinology Clinic, Stanford, California, United States
🇺🇸
University of Colorado Health Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
East Coast Institute for Research, Jacksonville, Florida, United States

and more 18 locations

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Phase 1

Recruiting

Conditions: ALS

Interventions: Other: Placebo
Drug: AMX0114

First Posted Date: 2024-10-30

Last Posted Date: 2025-02-07

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 48

Registration Number: NCT06665165

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada

AMX0035 and Progressive Supranuclear Palsy

Phase 2

Active, not recruiting

Conditions: Neurodegenerative Diseases
Atypical Parkinsonism
PSP
Progressive Supranuclear Palsy

Interventions: Other: Placebo
Drug: AMX0035

First Posted Date: 2023-11-08

Last Posted Date: 2024-12-20

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 110

Registration Number: NCT06122662

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Parkinson's & Movement Disorder Institute, Fountain Valley, California, United States

and more 59 locations

AMX0035 in Adult Patients With Wolfram Syndrome

Phase 2

Active, not recruiting

Conditions: Wolfram Syndrome

Interventions: Drug: AMX0035

First Posted Date: 2023-01-09

Last Posted Date: 2025-04-02

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 12

Registration Number: NCT05676034

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States

Extension Study Evaluating The Safety And Tolerability of AMX0035

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: AMX0035

First Posted Date: 2022-11-17

Last Posted Date: 2025-01-13

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 352

Registration Number: NCT05619783

Locations: 🇮🇹
University of Milan Medical School, Milan, Italy
🇮🇹
Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
🇫🇷
Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer Cellule Mutualisée de Recherche Clinique (CMRC), Bron, France

and more 42 locations

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2022-03-18

Last Posted Date: 2022-10-18

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Registration Number: NCT05286372

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Nova Southeastern University, Fort Lauderdale, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 18 locations

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Phase 3

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Other: Placebo
Drug: AMX0035

First Posted Date: 2021-08-25

Last Posted Date: 2024-08-14

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 664

Registration Number: NCT05021536

Locations: 🇺🇸
Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University School of Medicine Outpatient Center, Baltimore, Maryland, United States

and more 66 locations

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Phase 1

Active, not recruiting

Conditions: ALS

Interventions: Drug: AMX0035

First Posted Date: 2021-08-03

Last Posted Date: 2023-07-24

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 14

Registration Number: NCT04987671

Locations: 🇺🇸
Norman Fixel Institute for Neurological Diseases, Gainesville, Florida, United States

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: AMX0035

First Posted Date: 2020-08-18

Last Posted Date: 2023-04-07

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 28

Registration Number: NCT04516096

Locations: 🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States

and more 2 locations

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: AMX0035
Drug: Placebo

First Posted Date: 2018-05-23

Last Posted Date: 2025-03-07

Lead Sponsor: Amylyx Pharmaceuticals Inc.

Target Recruit Count: 95

Registration Number: NCT03533257

Locations: 🇺🇸
Genesis NeuroScience Clinic, Knoxville, Tennessee, United States
🇺🇸
Clinical Neuroscience Solutions, Inc. - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Clinical Neuroscience Solutions, Inc. - Orlando, Orlando, Florida, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy